Divis Laboratories Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tgw5dru88ta4eikm2zwugwxo.pdf

Key Takeaways


Custom Synthesis & the Mix Shift

Nilima Prasad Divi: "Let's not look at it on an individual quarter basis. Rather, we look at it on a year basis, where sometimes there's a lumpiness in one quarter and there is not so much of a custom synthesis business, but more of a generic business in another quarter."

Capex Commercialisation: The Three Big Bets

Dr. Kiran S. Divi: "I wish to share more, but I'm bound by CDAs not to share. All I can say is the validations have been completed, and we would be going commercial as and when the qualifications with the agencies are completed."

Peptides: The Next Leg of the Story

Dr. Kiran S. Divi: "I think we are the only ones who start from basic raw materials, build our own peptide building blocks... we have a complete chain of backward integration, which gives us a much more better opportunity compared to others."

Generic Business & Pricing Dynamics

Dr. Kiran S. Divi: "Whatever you're seeing right now is a market correction based on the raw material prices that have taken a substantial hit. It's not based on the markets have corrected and the pricing pressure has gone down."

Supply Chain, Costs & the Inventory Bet


Competitive Positioning & the CDMO Pitch

Dr. Kiran S. Divi: "It's not about pricing. It's not the only thing innovators look at. They look at sustainability, they look at safety issues. They look at your EHS capabilities, your effluent management system, your employee health care system."

Guidance & Commitments

CommitmentSpecificsTimeline
Double-digit revenue growthFull-year growth "no matter what"FY27
Full-year gross marginComparable to or slightly better than ~60%FY27
Full-year EBITDA marginSimilar to last yearFY27
Generic DMF commercialisationCommercial volumes from 4 filed DMFs beginNext 3–6 months
Contrast Media – Iodine, second customerSubstantial quantities to begin shippingNext few months
Inventory strategy3-month rolling buffer maintainedAs long as macro uncertainty persists

Key Metrics

MetricQ1 FY27
Consolidated total income₹3,144 cr, vs ₹2,529 cr in Q1 FY26
Standalone total income₹3,037 cr, vs ₹2,476 cr in Q1 FY26
Standalone constant-currency revenue growth10% YoY
Profit before tax (consolidated)₹1,180 cr, vs ₹733 cr in Q1 FY26
Profit after tax (consolidated)₹902 cr, vs ₹545 cr in Q1 FY26
Gross marginClose to 68% for the quarter; management notes lumpiness and does not expect this level to be consistent throughout the year
Net material consumption31.2% of standalone revenue from operations
Net forex loss₹7 cr loss, vs net forex gain of ₹39 cr in Q1 FY26
Custom Synthesis revenue share60% of standalone revenue
Generics revenue share40% of standalone revenue
Global nutraceutical revenue₹298 cr, vs ₹250 cr in Q1 FY26 and ~₹240 cr in Q4 FY26
Exports share of standalone revenueApproximately 90%
Europe and North America share of exports75%
Overall capacity utilization80–85% across all three units
Assets capitalized during the quarter₹451 cr
Capital work in progress₹2,034 cr as of June 30, 2026
Cash and cash equivalents₹3,611 cr as of quarter-end
Trade receivables₹3,056 cr as of quarter-end
Inventory₹4,413 cr as of quarter-end
Change in inventory~₹500 cr for the quarter, vs ₹50–100 cr in prior quarters and ~₹300 cr for full year FY26; driven by 3-month rolling raw material stocking and validation batch production
Three major capex projects total outlay~₹2,000 cr, approximately 70% capitalized so far
Commercialized or near-commercialized Custom Synthesis projectsClose to 18–20 projects